A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eribulin|DRUG: Carboplatin
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Collaborators: Eisai Inc.